Engineering adult stem cells for cancer immunotherapy

Wesley Burnside, Yan Cui

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Stem cells are rare populations of multipotent and undifferentiated progenitors, demonstrating an unlimited self-renewal capacity and high plasticity. After isolation from embryonic or adult tissues, stem cells can be expanded and manipulated ex vivo for therapeutic use. With recent advances in our understanding of stem cell biology, their pluripotency and longevity, and especially, the realization of their tumoritropic migratory property, stem cells are thought to be ideal candidates as vehicles for long-term and tissue-specific transgene delivery for cancer therapeutics. Stem cell-based approaches directly modifying, attracting, or enhancing the function of immune effector cells, such as T cells or APCs, and enhancing tumor killing have been proven feasible. However, the clinical efficacy of the engineered adult stem cells for specific and targeted cancer treatment has yet to be attested. With increased venues of stem cell generation, separation, ex vivo expansion, and improvement in targeted gene delivery vehicles, it is expected that broadened applications and improved clinical outcome of adult stem cell-based cancer treatment could be realized in the near future. Here, we review the rationale and current status of adult stem cell-based cancer immune therapy in experimental models and early clinical trials and extend our discussion to prospects for clinical application.

Original languageEnglish (US)
Title of host publicationTargeted Cancer Immune Therapy
PublisherSpringer New York
Pages191-206
Number of pages16
ISBN (Print)9781441901699
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Adult Stem Cells
Stem cells
Immunotherapy
Stem Cells
Neoplasms
Oncology
Cell Separation
Therapeutic Uses
Therapeutics
Transgenes
Cell Biology
Theoretical Models
Cytology
Tissue
Clinical Trials
T-Lymphocytes
T-cells
Plasticity
Tumors
Population

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Burnside, W., & Cui, Y. (2009). Engineering adult stem cells for cancer immunotherapy. In Targeted Cancer Immune Therapy (pp. 191-206). Springer New York. https://doi.org/10.1007/978-1-4419-0170-5_11

Engineering adult stem cells for cancer immunotherapy. / Burnside, Wesley; Cui, Yan.

Targeted Cancer Immune Therapy. Springer New York, 2009. p. 191-206.

Research output: Chapter in Book/Report/Conference proceedingChapter

Burnside, W & Cui, Y 2009, Engineering adult stem cells for cancer immunotherapy. in Targeted Cancer Immune Therapy. Springer New York, pp. 191-206. https://doi.org/10.1007/978-1-4419-0170-5_11
Burnside W, Cui Y. Engineering adult stem cells for cancer immunotherapy. In Targeted Cancer Immune Therapy. Springer New York. 2009. p. 191-206 https://doi.org/10.1007/978-1-4419-0170-5_11
Burnside, Wesley ; Cui, Yan. / Engineering adult stem cells for cancer immunotherapy. Targeted Cancer Immune Therapy. Springer New York, 2009. pp. 191-206
@inbook{6356c00911444dbc831afac1a67bb355,
title = "Engineering adult stem cells for cancer immunotherapy",
abstract = "Stem cells are rare populations of multipotent and undifferentiated progenitors, demonstrating an unlimited self-renewal capacity and high plasticity. After isolation from embryonic or adult tissues, stem cells can be expanded and manipulated ex vivo for therapeutic use. With recent advances in our understanding of stem cell biology, their pluripotency and longevity, and especially, the realization of their tumoritropic migratory property, stem cells are thought to be ideal candidates as vehicles for long-term and tissue-specific transgene delivery for cancer therapeutics. Stem cell-based approaches directly modifying, attracting, or enhancing the function of immune effector cells, such as T cells or APCs, and enhancing tumor killing have been proven feasible. However, the clinical efficacy of the engineered adult stem cells for specific and targeted cancer treatment has yet to be attested. With increased venues of stem cell generation, separation, ex vivo expansion, and improvement in targeted gene delivery vehicles, it is expected that broadened applications and improved clinical outcome of adult stem cell-based cancer treatment could be realized in the near future. Here, we review the rationale and current status of adult stem cell-based cancer immune therapy in experimental models and early clinical trials and extend our discussion to prospects for clinical application.",
author = "Wesley Burnside and Yan Cui",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-1-4419-0170-5_11",
language = "English (US)",
isbn = "9781441901699",
pages = "191--206",
booktitle = "Targeted Cancer Immune Therapy",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - Engineering adult stem cells for cancer immunotherapy

AU - Burnside, Wesley

AU - Cui, Yan

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Stem cells are rare populations of multipotent and undifferentiated progenitors, demonstrating an unlimited self-renewal capacity and high plasticity. After isolation from embryonic or adult tissues, stem cells can be expanded and manipulated ex vivo for therapeutic use. With recent advances in our understanding of stem cell biology, their pluripotency and longevity, and especially, the realization of their tumoritropic migratory property, stem cells are thought to be ideal candidates as vehicles for long-term and tissue-specific transgene delivery for cancer therapeutics. Stem cell-based approaches directly modifying, attracting, or enhancing the function of immune effector cells, such as T cells or APCs, and enhancing tumor killing have been proven feasible. However, the clinical efficacy of the engineered adult stem cells for specific and targeted cancer treatment has yet to be attested. With increased venues of stem cell generation, separation, ex vivo expansion, and improvement in targeted gene delivery vehicles, it is expected that broadened applications and improved clinical outcome of adult stem cell-based cancer treatment could be realized in the near future. Here, we review the rationale and current status of adult stem cell-based cancer immune therapy in experimental models and early clinical trials and extend our discussion to prospects for clinical application.

AB - Stem cells are rare populations of multipotent and undifferentiated progenitors, demonstrating an unlimited self-renewal capacity and high plasticity. After isolation from embryonic or adult tissues, stem cells can be expanded and manipulated ex vivo for therapeutic use. With recent advances in our understanding of stem cell biology, their pluripotency and longevity, and especially, the realization of their tumoritropic migratory property, stem cells are thought to be ideal candidates as vehicles for long-term and tissue-specific transgene delivery for cancer therapeutics. Stem cell-based approaches directly modifying, attracting, or enhancing the function of immune effector cells, such as T cells or APCs, and enhancing tumor killing have been proven feasible. However, the clinical efficacy of the engineered adult stem cells for specific and targeted cancer treatment has yet to be attested. With increased venues of stem cell generation, separation, ex vivo expansion, and improvement in targeted gene delivery vehicles, it is expected that broadened applications and improved clinical outcome of adult stem cell-based cancer treatment could be realized in the near future. Here, we review the rationale and current status of adult stem cell-based cancer immune therapy in experimental models and early clinical trials and extend our discussion to prospects for clinical application.

UR - http://www.scopus.com/inward/record.url?scp=84900882156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900882156&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0170-5_11

DO - 10.1007/978-1-4419-0170-5_11

M3 - Chapter

AN - SCOPUS:84900882156

SN - 9781441901699

SP - 191

EP - 206

BT - Targeted Cancer Immune Therapy

PB - Springer New York

ER -